Eiger BioPharmaceuticals And 2 Other Penny Stocks Insiders Are Aggressively Buying
Benzinga · 01/26 14:18
BRIEF-Eiger Biopharmaceuticals Inc CFO To Resign Effective Jan 20 2023
Reuters · 01/09 22:09
Eiger BioPharmaceuticals Says On Jan. 3, 2023 Sriram Ryali Notified Co. Of Resignation As Chief Financial Officer Effective Jan. 20, 2023
Benzinga · 01/09 22:08
12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga · 01/04 21:30
Looking Into Eiger BioPharmaceuticals's Recent Short Interest
Benzinga · 01/03 18:09
HUYA, KALA and EIGR among mid-day gainers and losers
Seekingalpha · 12/28/2022 18:00
Insider Buy: Eiger Biopharmaceuticals
Insider Buy: Eiger Biopharmaceuticals
MT Newswires · 12/27/2022 17:47
Eiger BioPharmaceuticals Chief Executive David Cory Resigns; Interim CEO Named
Eiger BioPharmaceuticals Chief Executive David Cory Resigns; Interim CEO Named
MT Newswires · 12/16/2022 04:02
BRIEF-Eiger BioPharmaceuticals Announces Leadership Change
Reuters · 12/15/2022 22:50
Eiger BioPharmaceuticals Announced President and CEO David A. Cory Resigned; Dr. David Apelian Named Interim CEO
Benzinga · 12/15/2022 22:46
How Is The Market Feeling About Eiger BioPharmaceuticals?
Benzinga · 12/09/2022 14:37
S&P 500 Rises 0.5%; Ciena Posts Upbeat Q4 Results
Benzinga · 12/08/2022 19:41
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Benzinga · 12/08/2022 17:56
12 Health Care Stocks Moving In Thursday's Intraday Session
Benzinga · 12/08/2022 17:31
Nasdaq Gains 100 Points; Rent the Runway Shares Spike Higher
Benzinga · 12/08/2022 17:12
Eiger BioPharmaceuticals' Debt Overview
Benzinga · 12/08/2022 16:07
Dow Rises 150 Points; US Jobless Claims Increase To 230,000
Benzinga · 12/08/2022 15:03
Eiger Shares Tumble Despite Phase 3 Study Meets Primary Endpoint
Benzinga · 12/08/2022 14:19
BRIEF-Eiger Announces Lonafarnib-Based Treatments In Phase 3 D-Livr Trial In Hepatitis Delta Virus Achieve Statistical Significance
Reuters · 12/08/2022 14:09
Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced topline primary Week 48 data from its...
PR Newswire · 12/08/2022 13:00
Webull provides a variety of real-time EIGR stock news. You can receive the latest news about Eiger Biopharma through multiple platforms. This information may help you make smarter investment decisions.
About EIGR
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development of therapies to treat and cure Hepatitis Delta Virus (HDV), the severe form of viral hepatitis, and other serious diseases. Its clinical product candidates include Lonafarnib (LNF) for HDV, Peginterferon Lambda (lambda) for HDV and Covid-19, Avexitide in Post-Bariatric Hypoglycemia (PBH) and Avexitide in Congenital Hyperinsulinism (CHI). Lambda is a late-stage, type III, interferon (IFN), that stimulates immune responses that are critical for the development of host protection during viral infections. Avexitide is a peptide, which is developing as a treatment for congenital hyperinsulinism (HI). It is also developing lambda as an out-patient treatment for patients with mild and moderate COVID-19. The Company is also developing Avexitide as a treatment for post-bariatric hypoglycemia (PBH).